Ignite Creation Date:
2025-12-25 @ 2:23 AM
Ignite Modification Date:
2026-03-22 @ 2:51 PM
Study NCT ID:
NCT04118634
Status:
UNKNOWN
Last Update Posted:
2020-12-16
First Post:
2019-09-26
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Registry Study on Biomarkers of Pulmonary Embolism
Sponsor:
Beijing Institute of Heart, Lung and Blood Vessel Diseases
Organization:
Study Overview
Official Title:
Evaluation of Performances of Biomarkers in Pulmonary Embolism
Status:
UNKNOWN
Status Verified Date:
2019-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BIO-PE
Brief Summary:
The purpose of the study is to evaluate the value of biomarkers in the diagnosis and risk stratification of patients with suspected pulmonary embolism.
Detailed Description:
Management of patients with acute pulmonary embolism is a serious problem. The rapid and accurate diagnosis and risk stratification of these patients is an important unmet clinical need. The aim of the study is to evaluate the value of biomarkers, alone or in combination, in the diagnosis and risk stratification of patients with suspected pulmonary embolism presenting to the emergency department.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: